#Paris #France #AZmed #AZnod #Rayscan

AZmed Expands Its AI Portfolio with AZnod

AZmed, a pioneering force in the realm of artificial intelligence (AI) for radiology, recently announced the launch of its latest innovation, AZnod. This new tool has achieved CE marking and is poised to become an integral part of AZmed's Rayscan® product line. The introduction of AZnod signifies a key expansion for the company as it ventures beyond conventional X-ray analysis and embraces advanced computed tomography (CT) technology.

Addressing Lung Cancer Detection Challenges

Lung cancer screening is a vital procedure that plays a crucial role in the early detection of malignant nodules. However, interpreting low-dose CT scans can be a daunting task for radiologists, particularly when it comes to identifying small nodules that could vary in appearance, from solid masses to subtle ground-glass opacities. Early detection of these nodules is essential for improving patient survival rates since subsolid nodules, for instance, can often be challenging to visualize during initial assessments.

AZnod aims to address these challenges by providing a sophisticated AI-driven analysis tool that systematically evaluates CT scan images for nodules ranging from 3 mm to 30 mm in diameter. This capability ensures that medical imaging teams can adhere to established guidelines, such as Lung-RADS and Fleischner, while delivering reproducible assessments.

How AZnod Works

The AZnod system meticulously analyzes each individual slice of a CT scan, effectively identifying and characterizing nodules based on multiple criteria. It evaluates characteristics such as volume, long-axis diameter, and perpendicular diameters. Furthermore, AZnod classifies each detected nodule based on its density, morphology, internal composition, and anatomical location within the lungs. This automated process not only facilitates clinical assessments but also seamlessly integrates into existing diagnostic workflows without necessitating substantial changes in practice.

The AI model employed in AZnod is designed to process pseudonymized images, ensuring patient privacy while delivering structured output that clinicians can rely upon. Upon completion of the analysis, the system generates a detailed report for each detected nodule, complete with prioritization based on clinical relevance. The report features annotated visuals that illustrate nodule size in both millimeters and cubic millimeters, supplemented by essential diagnostic attributes, thereby aiding clinicians in more effective decision-making.

Availability and Impact on Healthcare

AZnod is now accessible for healthcare providers in CE-mark compliant markets, marking a significant milestone for AZmed as it enhances its offerings in the medical imaging field. The powerful combination of advanced AI technology and rigorous clinical assessment capabilities positions AZnod as a valuable asset in lung cancer screening programs.

By utilizing AZmed's technological innovations, healthcare professionals can enhance diagnostic consistency, ultimately improving operational efficiency in medical imaging. This is particularly crucial in the context of a growing demand for efficient lung cancer screening procedures.

AZmed, established in 2018, specializes in developing AI solutions that improve various aspects of medical imaging. With its existing Rayvolve® AI Suite, which includes FDA-cleared and CE-marked tools, AZmed's dedication to enhancing healthcare through technology is evident. With over 2,500 healthcare facilities globally using its solutions, the company's commitment to advancing diagnostic capabilities demonstrates significant potential for impacting patient care positively.

For further information on AZnod and to explore how AZmed's solutions can benefit your medical practice, visit the AZmed website or contact their team directly to learn more about the exciting opportunities this innovative tool presents to the healthcare sector.